FY2030 Earnings Forecast for Ardelyx Issued By HC Wainwright

Key Points

• HC Wainwright cut FY2030 EPS to $1.60 from $1.75 while maintaining a Buy rating and an $18.00 price target on Ardelyx.
• Q1 revenue beat with total product revenue ≈$93.4M and IBSRELA up ~58% y/y to $70.1M; the company reiterated full‑year revenue guidance of $410–$430M and reported cash of ≈$238.1M, but posted a GAAP EPS miss of ($0.15) and remains unprofitable.
• Analyst/market view: consensus rating is a "Moderate Buy" with an average target of $15.70; shares trade near $6.88 (52‑week range $3.21–$8.40) and the company has a market cap of about $1.69B.

Ardelyx, Inc. (NASDAQ:ARDX - Free Report) - Research analysts at HC Wainwright cut their FY2030 earnings per share estimates for Ardelyx in a research note issued on Friday, May 1st. HC Wainwright analyst M. Caufield now anticipates that the biopharmaceutical company will earn $1.60 per share for the year, down from their prior estimate of $1.75. HC Wainwright currently has a "Buy" rating and a $18.00 target price on the stock.

ARDX has been the topic of several other reports. BTIG Research reaffirmed a "buy" rating and issued a $17.00 price objective on shares of Ardelyx in a research report on Friday, February 20th. Piper Sandler raised Ardelyx from a "neutral" rating to an "overweight" rating and upped their price target for the company from $10.00 to $16.00 in a report on Thursday, January 8th. Williams Trading set a $17.00 price objective on Ardelyx in a report on Thursday, March 12th. Leerink Partners reissued an "outperform" rating on shares of Ardelyx in a research report on Thursday, March 12th. Finally, Raymond James Financial reaffirmed a "strong-buy" rating and set a $19.00 price target on shares of Ardelyx in a report on Thursday, January 8th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $15.70.

Ardelyx Stock Performance

Shares of NASDAQ ARDX opened at $6.88 on Monday. The firm's 50 day moving average price is $6.02 and its 200-day moving average price is $6.16. Ardelyx has a 52-week low of $3.21 and a 52-week high of $8.40. The company has a debt-to-equity ratio of 1.37, a quick ratio of 3.28 and a current ratio of 3.49. The company has a market cap of $1.69 billion, a PE ratio of -29.91 and a beta of 0.62.

Ardelyx (NASDAQ:ARDX - Get Free Report) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.13) by ($0.02). The firm had revenue of $94.47 million during the quarter, compared to the consensus estimate of $92.78 million. Ardelyx had a negative return on equity of 38.11% and a negative net margin of 13.58%.The business's revenue for the quarter was up 27.5% on a year-over-year basis. During the same quarter in the previous year, the firm earned ($0.17) EPS.

Institutional Investors Weigh In On Ardelyx

Several hedge funds and other institutional investors have recently made changes to their positions in ARDX. First Horizon Corp boosted its holdings in shares of Ardelyx by 120.4% in the fourth quarter. First Horizon Corp now owns 7,906 shares of the biopharmaceutical company's stock worth $46,000 after buying an additional 4,319 shares during the last quarter. SBI Securities Co. Ltd. increased its holdings in Ardelyx by 147.0% during the third quarter. SBI Securities Co. Ltd. now owns 10,253 shares of the biopharmaceutical company's stock valued at $56,000 after buying an additional 6,102 shares during the last quarter. Swiss Life Asset Management Ltd purchased a new stake in Ardelyx during the third quarter valued at approximately $57,000. Sumitomo Mitsui Trust Group Inc. bought a new position in Ardelyx in the fourth quarter worth approximately $60,000. Finally, State of Wyoming bought a new position in Ardelyx in the second quarter worth approximately $61,000. Hedge funds and other institutional investors own 58.92% of the company's stock.

Insider Activity

In related news, insider Eric Duane Foster sold 10,439 shares of the company's stock in a transaction on Friday, February 20th. The stock was sold at an average price of $5.85, for a total transaction of $61,068.15. Following the completion of the sale, the insider owned 425,970 shares in the company, valued at approximately $2,491,924.50. This represents a 2.39% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Mike Kelliher sold 9,595 shares of the stock in a transaction dated Friday, February 20th. The shares were sold at an average price of $5.85, for a total value of $56,130.75. Following the completion of the transaction, the insider directly owned 364,666 shares in the company, valued at approximately $2,133,296.10. This represents a 2.56% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 128,604 shares of company stock worth $751,917. Insiders own 4.80% of the company's stock.

Key Stories Impacting Ardelyx

Here are the key news stories impacting Ardelyx this week:

• Positive Sentiment: Q1 product and revenue strength: Ardelyx reported Q1 total product revenue of about $93.4M and overall revenue that beat estimates, driven by strong demand for IBSRELA which grew ~58% year‑over‑year to $70.1M — a key driver of the upside. Ardelyx Reports First-Quarter 2026 Financial Results
• Positive Sentiment: Company reiterated full‑year revenue guidance of $410–$430M and reported a solid cash balance (~$238.1M), which supports ongoing commercialization and strategic investments. Press Release
• Positive Sentiment: Unusual options activity: buyers acquired ~7,048 call options (≈+267% vs. typical), signaling speculative/structured bullish positioning into or after the print — this can amplify intraday upside. (trade report)
• Neutral Sentiment: Earnings call and management commentary emphasized continued commercial investment and pipeline progress; read the call highlights for detail on strategy and priorities. Earnings Call Highlights
• Neutral Sentiment: Full Q1 earnings call transcript is available for investors who want granular color on sales trends, patient starts, and SG&A/R&D pacing. Earnings Call Transcript
• Negative Sentiment: EPS miss: Ardelyx reported a GAAP loss of $0.15/share versus consensus loss of $0.13 (miss of $0.02); company remains unprofitable with negative net margin and return on equity metrics that could restrain some valuation upside. Zacks: Q1 loss, revenue beat

About Ardelyx

Ardelyx, Inc NASDAQ: ARDX is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing targeted small molecule drugs for cardio‐renal and gastrointestinal diseases. The company's lead marketed product, tenapanor (sold under the brand name XPHOZAH in the United States), is approved for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis. Ardelyx's proprietary approach targets epithelial transporters in the gastrointestinal tract, offering localized activity with limited systemic exposure.

Beyond tenapanor, Ardelyx's development pipeline includes treatments designed to address other complications in kidney disease and related metabolic disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.